Overview

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare the efficacy and safety of first-line icotinib treatment and first-line chemotherapy followed by maintenance treatment with icotinib.
Phase:
Phase 4
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.
Treatments:
Cisplatin
Docetaxel